BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu TH, Su WW, Yang CC, Yang CC, Kuo WH, Chen YY, Yeh YH, Chen SS, Tsao YY, Chen KM, Yan SL, Lai JH, Yao CD, Lim CH, Jen HH, Yeh YP, Chen SL, Chen HH, Chen SC; Changhua Hepatitis C Elimination Task Force. Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan. Am J Kidney Dis 2021:S0272-6386(21)00575-8. [PMID: 33940114 DOI: 10.1053/j.ajkd.2021.03.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee JJ, Chang JM, Yang LJ, Hsu CC, Lin MH, Lin MY. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010-2018. J Formos Med Assoc 2022:S0929-6646(21)00584-2. [PMID: 34996670 DOI: 10.1016/j.jfma.2021.12.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Liu CH, Peng CY, Kao WY, Yang SS, Shih YL, Lin CL, Tsai MK, Lee CY, Chang CC, Wu JH, Liu CJ, Su TH, Tseng TC, Chen PJ, Kao JH. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Aliment Pharmacol Ther 2021. [PMID: 34773272 DOI: 10.1111/apt.16697] [Reference Citation Analysis]
3 Su PY, Su WW, Hsu YC, Wang SY, Chiu PF, Yen HH. Micro-Elimination of Hepatitis C among Patients with Kidney Disease by Using Electronic Reminder System-A Hospital-Based Experience. J Clin Med 2022;11:423. [PMID: 35054120 DOI: 10.3390/jcm11020423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Jadoul M, Labriola L, Gordon CE. HCV Can and Should Be Eliminated From Dialysis Units. Am J Kidney Dis 2021;78:487-8. [PMID: 34144101 DOI: 10.1053/j.ajkd.2021.06.001] [Reference Citation Analysis]
5 Gan L, Wang D, Bieber B, Mccullough K, Jadoul M, Pisoni RL, Hou F, Liang X, Ni Z, Chen X, Chen Y, Zuo L. Hepatitis C Prevalence, Incidence, and Treatment in Chinese Hemodialysis Patients: Results From the Dialysis Outcomes and Practice Patterns Study-China (2019–21). Front Med 2022;9:910840. [DOI: 10.3389/fmed.2022.910840] [Reference Citation Analysis]
6 LeBlanc EV, Kim Y, Capicciotti CJ, Colpitts CC. Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies. Pathogens 2021;10:685. [PMID: 34205894 DOI: 10.3390/pathogens10060685] [Reference Citation Analysis]
7 Chien RN, Lu SN, Pwu RF, Wu GH, Yang WW, Liu CL. Taiwan accelerates its efforts to eliminate hepatitis C. Glob Health Med 2021;3:293-300. [PMID: 34782872 DOI: 10.35772/ghm.2021.01064] [Reference Citation Analysis]
8 Fabrizi F, Cerutti R, Messa P. An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease. Pathogens 2021;10:1381. [PMID: 34832537 DOI: 10.3390/pathogens10111381] [Reference Citation Analysis]